Targeting cyclin-dependent kinases in anti-neoplastic therapy

Current Opinion in Cell Biology

Volumn 25, Issue 6, 2013, Pages 772-779

  Bruyère, Céline ^a   Meijer, Laurent ^a  

^a Centre de Perharidy   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; LETROZOLE; OBATOCLAX; PALBOCICLIB; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;

CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIVISION; GLIOBLASTOMA; HUMAN; MITOSIS; MYELOMA; NONHUMAN; PHOSPHORYLATION AND DEPHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; THERAPY EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLIN E; CYCLIN-DEPENDENT KINASES; HUMANS; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NEOPLASMS; ONCOGENE PROTEIN P55(V-MYC); PROTEIN KINASE INHIBITORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84887622751     PISSN: 09550674     EISSN: 18790410     Source Type: Journal    
DOI: 10.1016/j.ceb.2013.08.004     Document Type: Review

References (84)

1. Meijer L. Le cycle de division cellulaire et sa régulation. Oncologie 2003, 5:311-326.
2. Morgan D.O. The Cell Cycle: Principles of Control 2007, New Science Press Limited, 297 pp.
3. Malumbres M., Harlow E., Hunt T., Hunter T., Lahti J.M., Manning G., Morgan D.O., Tsai L.H., Wolgemuth D.J. Cyclin-dependent kinases: a family portrait. Nat Cell Biol 2009, 11:1275-1276.
4. Lim S., Kaldis P. Cdks, cyclins and CKIs: roles beyond cell cycle regulation. Development 2013, 140:3079-3093.
5. Fisher R.P. The CDK network: linking cycles of cell division and gene expression. Genes Cancer 2012, 3:731-738.
6. Eglen R., Reisine T. Drug discovery and the human kinome: recent trends. Pharmacol Ther 2011, 130:144-156.
7. Via M.C. Kinase-Targeted Therapeutics: Development Pipelines, Challenges, and Opportunities 2011, Cambridge Healthtech Institute, 124 pp.
8. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Trends Cell Biol 1996, 6:393-397.
9. Meijer L., Kim S.H. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol, "Cell Cycle Control" 1997, 283:113-128.
10. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002, 23:417-425.
11. Johnson N., Shapiro G.I. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors. Expert Opin Ther Targets 2010, 14:1199-1212.
12. Galons H., Oumata N., Meijer L. Cyclin-dependent kinase inhibitors: a survey of recent patent literature. Expert Opin Ther Pat 2010, 20:377-404.
13. Galons H., Oumata N., Gloulou O., Meijer L. Cyclin-dependent kinase inhibitors closer to market launch?. Expert Opin Ther Pat 2013, 23:945-963.
14. Wesierska-Gadek J., Kramer M.P. The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules. Future Med Chem 2012, 4:395-424.
15. Gallorini M.L., Cataldi A., di Giacomo V. Cyclin-dependent kinase modulators and cancer therapy. Biodrugs 2013, 26:1-15.
16. Abate A.A., Pentimalli F., Esposito L., Giordano A. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview. Expert Opin Investig Drugs 2013, 22:895-906.
17. Bose P., Simmons G.L., Grant S. Cyclin-dependent kinase inhibitor therapy for hematologic malignancies. Expert Opin Investig Drugs 2013, 22:723-738.
18. Esposito L., Indovina P., Magnotti F., Conti D., Giordano A. Anticancer therapeutic strategies based on CDK inhibitors. Curr Pharm Des 2013, 19:5327-5332.
19. Blachly J.S., Byrd J.C. Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma 2013, (Epub ahead of print).
20. Diaz-Moralli S., Tarrado-Castellarnau M., Miranda A., Cascante M. Targeting cell cycle regulation in cancer therapy. Pharmacol Ther 2013, 138:255-271.
21. Bettayeb K., Oumata N., Echalier A., Ferandin Y., Endicott J.A., Galons H., Meijer L. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008, 27:5797-5807.
22. Echalier A., Bettayeb K., Ferandin Y., Lozach O., Clément M., Valette A., Liger F., Marquet B., Morris J.C., Endicott J.A., et al. Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. J Med Chem 2008, 51:737-751.
23. Echalier A., Cot E., Camasses A., Hodimont E., Hoh F., Jay P., Sheinerman F., Krasinska L., Fisher D. An integrated chemical biology approach provides insight into Cdk2 functional redundancy and inhibitor sensitivity. Chem Biol 2012, 19:1028-1040.
24. Day P.J., Cleasby A., Tickle I.J., O'Reilly M., Coyle J.E., Holding F.P., McMenamin R.L., Yon J., Chopra R., Lengauer C., Jhoti H. Crystal structure of human CDK4 in complex with a D-type cyclin. Proc Natl Acad Sci USA 2009, 106:4166-4170.
25. Takaki T., Echalier A., Brown N.R., Hunt T., Endicott J.A., Noble M.E. The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc Natl Acad Sci USA 2009, 106:4171-4176.
26. Mapelli M., Massimiliano L., Crovace C., Seeliger M., Tsai L.H., Meijer L., Musacchio A. Mechanism of CDK5/p25 binding by CDK inhibitors. J Med Chem 2005, 48:671-679.
27. Lu H., Chang D.J., Baratte B., Meijer L., Schulze-Gahmen U. Crystal structure of a human cyclin-dependent kinase 6 complex with a flavonol inhibitor, fisetin. J Med Chem 2005, 48:737-743.
28. Lolli G., Lowe E.D., Brown N.R., Johnson L.N. The crystal structure of human CDK7 and its protein recognition properties. Structure 2004, 12:2067-2079.
29. Schneider E.V., Böttcher J., Blaesse M., Neumann L., Huber R., Maskos K. The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder. J Mol Biol 2011, 412:251-266.
30. Baumli S., Lolli G., Lowe E.D., Troiani S., Rusconi L., Bullock A.N., Debreczeni J.E., Knapp S., Johnson L.N. The structure of P-TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation. EMBO J 2008, 27:1907-1918.
31. Bettayeb K., Baunbæk D., Delehouzé C., Loaëc N., Hole A., Baumli S., Endicott J.A., Douc-Rasy S., Bénard J., Oumata N., et al. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cell lines. Genes Cancer 2010, 1:369-380.
32. Shao H., Shi S., Huang S., Hole A.J., Abbas A.Y., Baumli S., Liu X., Lam F., Foley D.W., Fischer P.M., et al. Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, X-ray crystal structures, structure-activity relationship, and anticancer activities. J Med Chem 2013, 56:640-659.
33. Lolli G. Structural dissection of cyclin dependent kinases regulation and protein recognition properties. Cell Cycle 2010, 9:1551-1561.
34. Meijer L., Bettayeb K., Galons H. Roscovitine (CYC202, Seliciclib). Monographs on Enzyme Inhibitors. CDK Inhibitors and Their Potential as Anti-tumor Agents 2006, vol 2:187-226. CRC Press, Taylor & Francis, Boca Raton, FL, (chapter 9).
35. Anastassiadis T., Deacon S.W., Devarajan K., Ma H., Peterson J.R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011, 29:1039-1045.
36. Davis M.I., Hunt J.P., Herrgard S., Ciceri P., Wodicka L.M., Pallares G., Hocker M., Treiber D.K., Zarrinkar P.P. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011, 29:1046-1051.
37. Bach S., Knockaert M., Reinhardt J., Lozach O., Schmitt S., Baratte B., Koken M., Coburn S.P., Tang L., Jiang T., et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005, 280:31208-31219.
38. Delehouzé C., Gödl K., Loaëc N., Bruyère C., Desban N., Oumata N., Galons H., Roumeliotis T.I., Giannopoulou E.G., Grenet J., et al. Down-regulation of amplified MYCN by CDK/CK1 inhibitors in neuroblastoma cells. Comparative 'omics' study of roscovitine and CR8 targets reveals convergence to the MYC pathway. Oncogene 2013, (in press).
39. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005, 23:329-336.
40. Johnson N., Li Y.C., Walton Z.E., Cheng K.A., Li D., Rodig S.J., Moreau L.A., Unitt C., Bronson R.T., Thomas H.D., et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011, 17:875-882.
41. Cheng C.K., Gustafson W.C., Charron E., Houseman B.T., Zunder E., Goga A., Gray N.S., Pollok B., Oakes S.A., James C.D., et al. Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma. Proc Natl Acad Sci USA 2012, 109:12722-12727.
42. Chen S., Dai Y., Pei X.Y., Myers J., Wang L., Kramer L.B., Garnett M., Schwartz D.M., Su F., Simmons G.L., et al. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Cancer Res 2012, 72:4225-4237.
43. Lange C.A., Yee D. Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer. Endocr Relat Cancer 2011, 18:C19-C24.
44. Baker S.J., Reddy E.P. CDK4: a key player in the cell cycle, development, and cancer. Genes Cancer 2012, 3:658-669.
45. Guha M. Blockbuster dreams for Pfizer's CDK inhibitor. Nat Biotechnol 2013, 31:187.
46. Keyomarsi K., Tucker S.L., Buchholz T.A., Callister M., Ding Y., Hortobagyi G.N., Bedrosian I., Knickerbocker C., Toyofuku W., Lowe M., et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002, 347:1566-1575. Erratum in: N Engl J Med 2003, 348:186.
47. Hunt K.K., Wingate H., Yokota T., Liu Y., Mills G.B., Zhang F., Fang B., Su C.H., Zhang M., Yi M., Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res 2013, 15:R3.
48. Akli S., Van Pelt C.S., Bui T., Meijer L., Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res 2011, 71:3377-3386.
49. Mittendorf E.A., Liu Y., Tucker S.L., McKenzie T., Qiao N., Akli S., Biernacka A., Liu Y., Meijer L., Keyomarsi K., Hunt K.K. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene 2010, 29:3896-3907.
50. Sjostrom S.K., Finn G., Hahn W.C., Rowitch D.H., Kenney A.M. The Cdk1 complex plays a prime role in regulating N-myc phosphorylation and turnover in neural precursors. Dev Cell 2005, 9:327-338.
51. Goga A., Yang D., Tward A.D., Morgan D.O., Bishop J.M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med 2007, 13:820-827.
52. Hydbring P., Bahram F., Su Y., Tronnersjö S., Högstrand K., von der Lehr N., Sharifi H.R., Lilischkis R., Hein N., Wu S., et al. Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci USA 2009, 107:58-63.
53. Molenaar J.J., Ebus M.E., Geerts D., Koster J., Lamers F., Valentijn L.J., Westerhout E.M., Versteeg R., Caron H.N. Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells. Proc Natl Acad Sci USA 2009, 106:12968-12973.
54. Otto T., Horn S., Brockmann M., Eilers U., Schüttrumpf L., Popov N., Kenney A.M., Schulte J.H., Beijersbergen R., Christiansen H., et al. Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 2009, 15:67-78.
55. Campaner S., Doni M., Hydbring P., Verrecchia A., Bianchi L., Sardella D., Schleker T., Perna D., Tronnersjö S., Murga M., et al. Cdk2 suppresses cellular senescence induced by the c-myc oncogene. Nat Cell Biol 2010, 12:54-59.
56. Wang X., Cunningham M., Zhang X., Tokarz S., Laraway B., Troxell M., Sears R.C. Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res 2011, 71:925-936.
57. Horiuchi D., Kusdra L., Huskey N.E., Chandriani S., Lenburg M.E., Gonzalez-Angulo A.M., Creasman K.J., Bazarov A.V., Smyth J.W., Davis S.E., et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012, 209:679-696.
58. Cepeda D., Ng H.F., Sharifi H.R., Mahmoudi S., Cerrato V.S., Fredlund E., Magnusson K., Nilsson H., Malyukova A., Rantala J., et al. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med 2013, 5:999-1018.
59. Toyoshima M., Howie H.L., Imakura M., Walsh R.M., Annis J.E., Chang A.N., Frazier J., Chau B.N., Loboda A., Linsley P.S., et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Natl Acad Sci USA 2012, 109:9545-9950.
60. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
61. Mertz J.A., Conery A.R., Bryant B.M., Sandy P., Balasubramanian S., Mele D.A., Bergeron L., Sims R.J., Targeting M.Y.C. dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011, 108:16669-16674.
62. Faisal A., Vaughan L., Bavetsias V., Sun C., Atrash B., Avery S., Jamin Y., Robinson S.P., Workman P., Blagg J., et al. The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther 2011, 10:2115-2123.
63. Schwickart M., Huang X., Lill J.R., Liu J., Ferrando R., French D.M., Maecker H., O'Rourke K., Bazan F., Eastham-Anderson J., et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463:103-107.
64. Lestini B.J., Goldsmith K.C., Fluchel M.N., Liu X., Chen N.L., Goyal B., Pawel B.R., Hogarty M.D. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009, 8:1587-1595.
65. Hahntow I.N., Schneller F., Oelsner M., Weick K., Ringshausen I., Fend F., Peschel C., Decker T. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004, 18:747-755.
66. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007, 67:782-791.
67. Hallaert D.Y., Spijker R., Jak M., Derks I.A., Alves N.L., Wensveen F.M., de Boer J.P., de Jong D., Green S.R., van Oers M.H., Eldering E. Crosstalk among Bcl-2 family members in B-CLL: seliciclib acts via the Mcl-1/Noxa axis and gradual exhaustion of Bcl-2 protection. Cell Death Differ 2007, 14:1958-1967.
68. Cosimo E., McCaig A.M., Carter-Brzezinski L.J.M., Wheadon H., Leach M.T., Lester K., Berthou C., Durieu E., Oumata N., Galons H., et al. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells. Clin Cancer Res 2013, 19:2393-2405.
69. McCallum D.E., Melville J., Frame S., Watt K., Anderson S., Gianella-Borradori A., Lane D.P., Green S.R. Seliciclib (CYC202 R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 2005, 65:5399-5407.
70. Raje N., Kumar S., Hideshima T., Roccaro A., Ishitsuka K., Yasui H., Shiraishi N., Chauhan D., Munshi N.C., Green S.R., Anderson K.C. Seliciclib (CYC202 or R-roscovitine) a small-molecule cyclin-dependent kinase inhibitor mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 2005, 106:1042-1047.
71. Komina O., Nosske E., Maurer M., Wesierska-Gadek J. Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells. J Exp Ther Oncol 2011, 9:27-35.
72. Josefsberg Ben-Yehoshua L., Beider K., Shimoni A., Ostrovsky O., Samookh M., Peled A., Nagler A. Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death. PLoS One 2012, 7:e33856.
73. Alvarez-Fernández S., Ortiz-Ruiz M.J., Parrott T., Zaknoen S., Ocio E.M., San Miguel J., Burrows F.J., Esparís-Ogando A., Pandiella A. Potent antimyeloma activity of a novel ERK5/CDK inhibitor. Clin Cancer Res 2013, 19:2677-2687.
74. Hui A.B., Yue S., Shi W., Alajez N.M., Ito E., Green S.R., Frame S., O'Sullivan B., Liu F.F. Therapeutic efficacy of seliciclib in combination with ionizing radiation for human nasopharyngeal carcinoma. Clin Cancer Res 2009, 15:3716-3724.
75. Porter D.C., Farmaki E., Altilia S., Schools G.P., West D.K., Chen M., Chang B.D., Puzyrev A.T., Lim C.U., Rokow-Kittell R., et al. Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proc Natl Acad Sci USA 2012, 109:13799-13804.
76. Schneider E.V., Böttcher J., Huber R., Maskos K., Neumann L. Structure-kinetic relationship study of CDK8/CycC specific compounds. Proc Natl Acad Sci USA 2013, 110:8081-8086.
77. Szilagyi Z., Gustafsson C.M. Emerging roles of Cdk8 in cell cycle control. Biochim Biophys Acta 2013, 1829:916-920.
78. Guen V, Gamble C, Flajolet M, Unger S, Thollet A, Ferandin Y, Superti-Furga A, Cohen PA, Meijer L, Colas P: CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome. Proc Natl Acad Sci, in press.
79. Duan Z., Zhang J., Choy E., Harmon D., Liu X., Nielsen P., Mankin H., Gray N.S., Hornicek F.J. Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation. Clin Cancer Res 2012, 18:4580-4588.
80. Cheng S.W., Kuzyk M.A., Moradian A., Ichu T.A., Chang V.C., Tien J.F., Vollett S.E., Griffith M., Marra M.A., Morin G.B. Interaction of cyclin-dependent kinase 12/CrkRS with cyclin K1 is required for the phosphorylation of the C-terminal domain of RNA polymerase II. Mol Cell Biol 2012, 32:4691-4704.
81. Kohoutek J., Blazek D. Cyclin K goes with Cdk12 and Cdk13. Cell Div 2012, 7:12.
82. Blazek D., Kohoutek J., Bartholomeeusen K., Johansen E., Hulinkova P., Luo Z., Cimermancic P., Ule J., Peterlin B.M. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev 2011, 25:2158-2172.
83. An X., Ng S.S., Xie D., Zeng Y.X., Sze J., Wang J., Chen Y.C., Chow B.K., Lu G., Poon W.S., et al. Functional characterisation of cell cycle-related kinase (CCRK) in colorectal cancer carcinogenesis. Eur J Cancer 2010, 46:1752-1761.
84. Tian Y., Wan H., Tan G. Cell cycle-related kinase in carcinogenesis. Oncol Lett 2012, 4:601-606.